Home / Healthcare / Healthcare News updates: Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX)

Healthcare News updates: Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX)

Valeant Pharmaceuticals International, Inc.’s (NYSE: VRX and TSX: VRX) wholly owned partner, Bausch + Lomb, a leading global eye health company, recently declared the introduction of Bausch + Lomb AQUALOX® contact lenses, the first new innovation in the bi-weekly contact lens category in half a decade, to the Japanese market. The innovative bi-weekly silicone hydrogel lens combines MoistureSeal® technology, which assists the lens maintain 95% of its moisture up to a full 16 hours, and provides patients maximum comfort throughout the day.
More than 25 countries, counting Canada, France, Germany, Korea, Malaysia and the United States, presently offer Bausch + Lomb AQUALOX contact lenses in the spherical modality (known as Bausch + Lomb ULTRA® contact lenses in all countries apart from Japan). In the future, Bausch + Lomb Japan plans to introduce Bausch + Lomb AQUALOX contact lens for Presbyopia to the Japan market followed by the toric version of the lens. (Both are already available in the United States).
“These innovative and unique contact lenses were developed in-house by our scientists and contact lens designers to offer an exceptional lens wearing experience,” said Joseph C. Papa, Chairman and CEO of Valeant. “We’re happy to offer this new advanced technology in bi-weekly contact lenses to patients across Japan, a key growth market for the company.”
In addition to the Bausch + Lomb AQUALOX lenses, the Bausch + Lomb Japan product portfolio features PureVision®2, SofLens® 59, and SofLens® 38 bi-weekly contact lenses, renu® fresh solution, the No. 1 multi-purpose contact lens solution in Japan, in addition to the following daily disposable contact lenses, Biotrue® ONEday, Biotrue ONEday for Presbyopia, and Medalist® ONEday.
About Bausch + Lomb
Bausch + Lomb, a Valeant Pharmaceuticals International, Inc. company, is a leading global eye health organization that is solely focused on protecting, enhancing and restoring people’s eyesight. Its core businesses include over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in our industry, which is available in more than 100 countries.

Check Also

News Recap: Twitter, Inc. (NYSE: TWTR)

Twitter, Inc. (NYSE: TWTR) recently declared the appointment of Ned Segal as Chief Financial Officer …